Corteva, Inc. $CTVA Shares Purchased by Kingsview Wealth Management LLC

Kingsview Wealth Management LLC grew its position in Corteva, Inc. (NYSE:CTVA) by 238.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 47,372 shares of the company’s stock after purchasing an additional 33,383 shares during the period. Kingsview Wealth Management LLC’s holdings in Corteva were worth $3,204,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Total Investment Management Inc. acquired a new position in Corteva during the second quarter valued at $27,000. Activest Wealth Management boosted its holdings in Corteva by 118.3% in the third quarter. Activest Wealth Management now owns 369 shares of the company’s stock worth $25,000 after purchasing an additional 200 shares in the last quarter. True Wealth Design LLC raised its stake in shares of Corteva by 209.5% in the 3rd quarter. True Wealth Design LLC now owns 390 shares of the company’s stock valued at $26,000 after acquiring an additional 264 shares in the last quarter. Twin Peaks Wealth Advisors LLC bought a new position in Corteva in the 2nd quarter worth $29,000. Finally, Redmont Wealth Advisors LLC acquired a new position in shares of Corteva during the 3rd quarter worth about $29,000. 81.54% of the stock is currently owned by institutional investors and hedge funds.

Corteva Price Performance

CTVA stock opened at $77.98 on Thursday. Corteva, Inc. has a 1 year low of $53.40 and a 1 year high of $80.90. The company has a market cap of $52.44 billion, a P/E ratio of 49.35, a PEG ratio of 2.70 and a beta of 0.72. The firm has a 50-day moving average of $72.63 and a 200 day moving average of $68.97. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.43 and a quick ratio of 0.96.

Corteva (NYSE:CTVA) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $0.22 earnings per share for the quarter, hitting the consensus estimate of $0.22. The company had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $4.23 billion. Corteva had a return on equity of 9.06% and a net margin of 6.29%.The firm’s revenue for the quarter was down 1.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.32 earnings per share. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, sell-side analysts forecast that Corteva, Inc. will post 2.96 EPS for the current year.

Corteva Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 16th. Investors of record on Monday, March 2nd will be paid a dividend of $0.18 per share. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $0.72 annualized dividend and a yield of 0.9%. Corteva’s payout ratio is presently 45.57%.

Insiders Place Their Bets

In other news, insider Brian Titus sold 8,311 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $76.55, for a total value of $636,207.05. Following the sale, the insider directly owned 8,090 shares of the company’s stock, valued at $619,289.50. The trade was a 50.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CTVA shares. Bank of America lifted their target price on Corteva from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Rothschild & Co Redburn lowered their price target on shares of Corteva from $71.00 to $65.00 and set a “neutral” rating on the stock in a report on Tuesday, November 11th. Mizuho raised their price objective on shares of Corteva from $80.00 to $82.00 and gave the stock an “outperform” rating in a report on Tuesday, February 17th. Wells Fargo & Company upped their target price on shares of Corteva from $77.00 to $85.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Finally, UBS Group lowered shares of Corteva from a “buy” rating to a “hold” rating in a research report on Monday, February 9th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, Corteva presently has a consensus rating of “Moderate Buy” and a consensus target price of $82.80.

Corteva Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.